Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 77 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Carrier State Clear all
Not listed No phase listed Observational

Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers

NCT00897455
View directory record Official record
Conditions
brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
Interventions
DNA analysis, mutation analysis, polymorphism analysis, laboratory biomarker analysis, evaluation of cancer risk factors
Genetic · Other · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years to 80 Years · Female only
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Oct 25, 2026, 7:47 PM EDT
Completed Phase 3 Interventional

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)

NCT00574132
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bapineuzumab 0.5 mg/kg, Placebo Control, Bapineuzumab 1.0 m/kg
Drug
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 88 Years
Enrollment
1,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
219
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 170 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 25, 2026, 7:47 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History Study - Mitochondrial Disease

NCT01532791
View directory record Official record
Conditions
MELAS or m.3243 A>G Mitochondrial DNA Mutation Carrier
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
4 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 25, 2026, 7:47 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers Results available

The Efficacy of Probiotics to Reduce Antepartum Group B Streptococcus Colonization.

NCT03696953
View directory record Official record
Conditions
Group B Streptococcus Carrier in Childbirth, Gastrointestinal Symptoms
Interventions
Florajen3
Biological
Lead sponsor
Marquette University
Other
Eligibility
18 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 25, 2026, 7:47 PM EDT
Completed Not applicable Interventional

An Open Trial Combining Zidovudine, Interferon-alfa, and Recombinant CD4-IgG With Transplantation of Syngeneic Bone Marrow and Peripheral Blood Lymphocytes From Healthy gp160-Immunized Donors in the Treatment of Patients With HIV Infection

NCT00000647
View directory record Official record
Conditions
HIV Infections
Interventions
CD4-IgG, Zidovudine, Interferon alfa-n1, Peripheral lymphocyte infusion, Bone marrow transplant
Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 25, 2026, 7:47 PM EDT
Terminated Phase 1 Interventional

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

NCT01233505
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ovarian Mucinous Cystadenocarcinoma, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Gastric Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
veliparib, capecitabine, oxaliplatin, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 25, 2026, 7:47 PM EDT
Completed Phase 1 Interventional

A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4 Immunoglobulin (rCd4-IgG) Administered by Intravenous Bolus in Patients With AIDS and AIDS Related Complex

NCT00000675
View directory record Official record
Conditions
HIV Infections
Interventions
CD4-IgG
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Stanford, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 7:47 PM EDT
Recruiting No phase listed Observational

The Duchenne Registry

NCT02069756
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Dystrophinopathy, Dystrophinopathy Symptomatic Female Carrier, Dystrophinopathy Female Carrier
Interventions
Not listed
Lead sponsor
The Duchenne Registry
Other
Eligibility
Not listed
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2047
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 25, 2026, 7:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer

NCT01219075
View directory record Official record
Conditions
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions
soy isoflavones, placebo, questionnaire administration, magnetic resonance imaging, biopsy, immunohistochemistry staining method, laboratory biomarker analysis, mammography
Dietary Supplement · Other · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
30 Years to 75 Years · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 25, 2026, 7:47 PM EDT
Withdrawn No phase listed Observational

Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers

NCT00899145
View directory record Official record
Conditions
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Breast Carcinoma
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years to 80 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 25, 2026, 7:47 PM EDT
Completed Phase 1 Interventional

A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4-Immunoglobulin G (rCD4-IgG) Administered by Intravenous Bolus Injection in Combination With Oral Zidovudine in Patients With AIDS and AIDS-Related Complex

NCT00000976
View directory record Official record
Conditions
HIV Infections
Interventions
CD4-IgG, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Diego, California • Miami, Florida • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2008 · Synced Oct 25, 2026, 7:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit

NCT02863809
View directory record Official record
Conditions
Keratolysis
Interventions
Riboflavin, Dextran, UVA Light Source
Drug · Device
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 25, 2026, 7:47 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever

NCT06799013
View directory record Official record
Conditions
Vaccine, Crimean-Congo Hemorrhagic Fever
Interventions
10 ug HDT 321, 25ug HDT-321, 50ug HDT-321
Biological
Lead sponsor
HDT Bio
Industry
Eligibility
18 Years to 64 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 25, 2026, 7:47 PM EDT
Completed No phase listed Observational

CureDuchenne Link®: A Resource for Research

NCT04972604
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Interventions
Not listed
Lead sponsor
CureDuchenne
Other
Eligibility
4 Weeks and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
10
States / cities
Little Rock, Arkansas • Newport Beach, California • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 25, 2026, 7:47 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Release Kinetics of rhBMP-2 Using E-PRF as an Autologous Carrier: An In Vitro Analysis

NCT04670965
View directory record Official record
Conditions
Bone Loss
Interventions
E-PRF/rhBMP-2 (similar ratios), E-PRF/ACS/rhBMP-2, rhBMP-2/E-PRF, E-PRF only
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 25, 2026, 7:47 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study to Eliminate Hib Carriage in Rural Alaska Native Villages

NCT00153556
View directory record Official record
Conditions
Haemophilus Influenzae Type B, Carrier State
Interventions
Hib conjugate vaccine (HbOC, Wyeth Vaccines)
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
0 Years and older
Enrollment
3,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2003
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Sep 12, 2005 · Synced Oct 25, 2026, 7:47 PM EDT
Completed No phase listed Observational

Staphylococcus Aureus Carrier Status in Breastfeeding Mothers and Infants and the Risk of Lactation Mastitis

NCT00620984
View directory record Official record
Conditions
Mastitis, Staphylococcus Aureus, Staphylococcal Infections
Interventions
Not listed
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older · Female only
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Oct 25, 2026, 7:47 PM EDT
Completed Not applicable Interventional

Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer

NCT01874184
View directory record Official record
Conditions
Atypical Ductal Breast Hyperplasia, Atypical Lobular Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Interventions
counseling intervention, behavioral dietary intervention, exercise intervention, questionnaire administration, laboratory biomarker analysis
Other · Behavioral
Lead sponsor
University of Washington
Other
Eligibility
35 Years to 65 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 25, 2026, 7:47 PM EDT
Completed No phase listed Observational

Estimation of the Carrier Frequency and Incidence of Smith-Lemli-Opitz Syndrome in African Americans

NCT00017732
View directory record Official record
Conditions
Smith-Lemli-Opitz Syndrome
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 25, 2026, 7:47 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Follow Up of Gestational Carriers and Intended Parents

NCT01219530
View directory record Official record
Conditions
Attitudes, Reactions, Psychopathology
Interventions
Not listed
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
21 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 25, 2026, 7:47 PM EDT
Recruiting No phase listed Observational

Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials

NCT07674758
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD), Cardiomyopathy, Becker Muscular Dystrophy, Carrier of Duchenne Muscular Dystrophy
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Sacramento, California • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 25, 2026, 7:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

NCT05453578
View directory record Official record
Conditions
Bacterial Disease Carrier, Cystic Fibrosis
Interventions
Placebo, WRAIR-PAM-CF1
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
19
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 25, 2026, 7:47 PM EDT
Withdrawn No phase listed Observational

Multi-disease Carrier Screening Test Validation

NCT01663584
View directory record Official record
Conditions
Spinal Muscular Atrophy (SMA), Carrier Screening, Genetic Testing
Interventions
Blood draw
Procedure
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
San Carlos, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 25, 2026, 7:47 PM EDT
Completed No phase listed Observational

Awareness and Attitudes Regarding Prenatal and Preimplantation Genetic Diagnosis for Inherited Breast/Ovarian Cancer Risk

NCT00735150
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
questionnaire, interview
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 39 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 11, 2010 · Synced Oct 25, 2026, 7:47 PM EDT